Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064338 | 1.00 | P2RY12 (0.48) | P2RY12AOC3KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL31050098 | 0.90 | RORC (0.48) | P2RY12SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30633888 | 0.87 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL30633890 | 0.87 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL23064284 | 0.87 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL23064317 | 0.87 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL23064282 | 0.87 | P2RY12 (0.46) | P2RY12 | |
| SCHEMBL23064356 | 0.84 | RORC (0.42) | P2RY12SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23064353 | 0.84 | RORC (0.42) | P2RY12SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30778002 | 0.84 | RORC (0.42) | P2RY12SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | SHINSHU UNIVERSITY (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4487848-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-01-08 | — | — | EP | disclosed |
| EP-4461296-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | Osaka University (JP) | 2024-11-13 | — | — | EP | disclosed |
| CN-118678955-A | Pharmaceutical composition for preventing and/or treating heart failure | 国立大学法人大阪大学 | 2024-09-20 | — | — | CN | disclosed |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | KYOTO UNIVERSITY (JP) | 2024-09-19 | — | — | US | disclosed |
| CN-112204017-B | Benzisoxazole compounds | 国立大学法人大阪大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11976062-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-117580577-A | Pharmaceutical composition for preventing and/or treating kidney injury and autophagy activator | 国立大学法人大阪大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023163203-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | 国立大学法人大阪大学 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023132208-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | 国立大学法人大阪大学 | 2023-07-13 | — | — | WO | disclosed |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | KYOTO UNIVERSITY (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2023276828-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | 国立大学法人大阪大学 | 2023-01-05 | — | — | WO | disclosed |
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) | 2021-08-05 | — | — | US | disclosed |
| EP-3789383-A1 | BENZISOXAZOLE COMPOUND | Osaka University (JP) | 2021-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | P2RY12 1892/4885AOC3 227/4885KDM4E 1084/4885 |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | ATG7, BECN1, SQSTM1 | P2RY12 465/4885AOC3 1211/4885KDM4E 2158/4885 |
| US-11976062-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | P2RY12 1903/4885AOC3 231/4885KDM4E 1080/4885 |
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | REN, ATP6V1B1, CYP2S1 | P2RY12 834/4885AOC3 441/4885KDM4E 3121/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | P2RY12 1892/4885AOC3 227/4885KDM4E 1084/4885 |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | P2RY12 1921/4885AOC3 242/4885KDM4E 969/4885 |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | CBR1, CYP2S1, CYP2F1 | P2RY12 974/4885AOC3 420/4885KDM4E 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.